| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06638307 A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer |
Trial sites expanded: 36 -> 42 locations |
| 2026-06-11 | NCT07198724 ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients… |
Sponsor changed: Sarah Sammons, MD -> Kristina A. Fanucci |
| 2026-05-28 | NCT06492616 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… |
Trial sites expanded: 536 -> 541 locations |
| 2026-05-23 | NCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With… |
date change Completion moved earlier: 2035-01-01 -> 2033-09-30 |
| 2026-05-16 | NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted… |
Trial sites expanded: 303 -> 342 locations |
| 2026-05-16 | NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing… |
date change Primary completion pushed: 2026-07-31 -> 2027-07-31 |
| 2026-05-16 | NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing… |
date change Completion pushed: 2026-07-31 -> 2027-07-31 |
| 2026-05-14 | NCT07455903 Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients… |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07634601 Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07620067 GnRH for Luteal Support - Mechanism of Action | Recruiting | |
| 2026-05-28 | NCT07612215 Elacestrant in Advanced Triple Positive Breast Cancer | Phase 1/2 | Recruiting |
| 2026-05-19 | NCT07596212 BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer… | Advanced Breast Cancer | Recruiting |
| NCT06513962 | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With… | Hematopoietic and Lymphatic System Neoplasm | Recruiting |
| NCT07242352 | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine… | Breast Cancer | Recruiting |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted… | Biochemically Recurrent Prostate Carcinoma | Recruiting |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | ER-positive Breast Cancer | Recruiting |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… | Breast Cancer | Recruiting |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Recruiting |
| NCT05296798 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo… | Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT05306340 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With… | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment… | Prostate Adenocarcinoma | Active, Not Recruiting |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less… | Prostate Adenocarcinoma | Active, Not Recruiting |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy… | Prostate Carcinoma | Active, Not Recruiting |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | Prostate Cancer | Active, Not Recruiting |
| NCT04546009 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib… | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With… | Early Breast Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04356664 | Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis… | Endometriosis | Recruiting |
| Phase 2 | |||
| NCT07222215 | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer… | Estrogen-receptor-positive Breast Cancer | Recruiting |
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With… | Prostate Cancer | Recruiting |
| NCT07254429 | COMPASS - COpenhagen MenoPAuSe Study | Menopausal Osteoporosis | Recruiting |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT06378866 | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway… | Recurrent Castration-Sensitive Prostate Carcinoma | Recruiting |
| NCT05982093 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | Breast Cancer | Recruiting |
| NCT06923527 | Circulating Tumor DNA | ER+ Breast Cancer | Recruiting |
| NCT07455903 | Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients… | Prostate Cancer | Recruiting |
| NCT06075953 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active… | Ductal Carcinoma in Situ | Recruiting |